Alto Neuroscience, Inc. (ANRO)Healthcare | Biotechnology | Mountain View, United States | NYSE
27.55 USD
+1.49
(5.717%)
⇧
(April 17, 2026, 2:28 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:53 p.m. EDT
ANRO is a highly volatile stock with a significant short interest and negative fundamentals, making it a risky short-term play. The recent news includes mixed analyst opinions, with some recommending a buy while others are pessimistic. The current price is near the 52-week high, but the stock has a history of significant price swings. While there are some positive analyst ratings, the overall fundamentals and high volatility make it a speculative investment. Long-term investors should be cautious, as the stock lacks consistent dividends and has a negative earnings outlook. Short-term traders might consider the stock for momentum or options strategies, but the high risk should be weighed against potential rewards. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.202188 |
| AutoARIMA | 0.204357 |
| AutoETS | 0.204358 |
| AutoTheta | 0.229625 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 10.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.378 |
| Excess Kurtosis | -0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.851 |
| Market Cap | 965,699,264 |
| Forward P/E | -12.11 |
| Beta | 2.06 |
| Website | https://www.altoneuroscience.com |
As of April 11, 2026, 2:53 p.m. EDT: Options speculators are showing mixed signals. The calls show a concentration of open interest (OI) around the 22.5 strike, which is near the current price, suggesting some bullish sentiment. However, the puts also show significant OI around the 22.5 strike, indicating potential bearishness. The high IV (implied volatility) on puts, especially on the 2026-10-16 expiration, suggests increased uncertainty or fear, which could lead to a volatile price movement. The overall options activity indicates a cautious outlook with potential for both upward and downward moves.
| Attribute | Value |
|---|---|
| 52 Week Change | 10.2327585 |
| Address1 | 650 Castro Street |
| Address2 | Suite 450 |
| All Time High | 27.5 |
| All Time Low | 1.6 |
| Ask | 27.52 |
| Ask Size | 100 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 394,870 |
| Average Daily Volume3 Month | 280,429 |
| Average Volume | 280,429 |
| Average Volume10Days | 394,870 |
| Beta | 2.059 |
| Bid | 27.35 |
| Bid Size | 100 |
| Book Value | 4.735 |
| City | Mountain View |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.5499 |
| Current Ratio | 15.693 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 28.11 |
| Day Low | 25.805 |
| Debt To Equity | 15.851 |
| Display Name | Alto Neuroscience |
| Earnings Timestamp | 1,773,664,200 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -65,703,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.349 |
| Enterprise Value | 679,974,144 |
| Eps Current Year | -2.1 |
| Eps Forward | -2.275 |
| Eps Trailing Twelve Months | -2.19 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.5634 |
| Fifty Day Average Change | 6.9865 |
| Fifty Day Average Change Percent | 0.3397541 |
| Fifty Two Week Change Percent | 1,023.2759 |
| Fifty Two Week High | 28.11 |
| Fifty Two Week High Change | -0.56010056 |
| Fifty Two Week High Change Percent | -0.019925313 |
| Fifty Two Week Low | 2.12 |
| Fifty Two Week Low Change | 25.429901 |
| Fifty Two Week Low Change Percent | 11.995237 |
| Fifty Two Week Range | 2.12 - 28.11 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,706,884,200,000 |
| Float Shares | 19,191,588 |
| Forward Eps | -2.275 |
| Forward P E | -12.109846 |
| Free Cashflow | -33,950,624 |
| Full Exchange Name | NYSE |
| Full Time Employees | 68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.062529996 |
| Held Percent Institutions | 0.7704 |
| Implied Shares Outstanding | 35,052,731 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California. |
| Market | us_market |
| Market Cap | 965,699,264 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_1675972978 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -63,238,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 913,474,169 |
| Number Of Analyst Opinions | 9 |
| Open | 26.25 |
| Operating Cashflow | -51,769,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 200 0412 |
| Previous Close | 26.06 |
| Price Eps Current Year | -13.119 |
| Price Hint | 2 |
| Price To Book | 5.8183527 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.584 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | 1.4899006 |
| Regular Market Change Percent | 5.717193 |
| Regular Market Day High | 28.11 |
| Regular Market Day Low | 25.805 |
| Regular Market Day Range | 25.805 - 28.11 |
| Regular Market Open | 26.25 |
| Regular Market Previous Close | 26.06 |
| Regular Market Price | 27.5499 |
| Regular Market Time | 1,776,450,482 |
| Regular Market Volume | 180,447 |
| Return On Assets | -0.22900999 |
| Return On Equity | -0.41796002 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 35,052,731 |
| Shares Percent Shares Out | 0.0642 |
| Shares Short | 2,051,993 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,043,099 |
| Short Name | Alto Neuroscience, Inc. |
| Short Percent Of Float | 0.0783 |
| Short Ratio | 6.52 |
| Source Interval | 15 |
| State | CA |
| Symbol | ANRO |
| Target High Price | 50.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 35.24444 |
| Target Median Price | 35.0 |
| Total Cash | 176,484,000 |
| Total Cash Per Share | 5.525 |
| Total Debt | 23,958,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.03835 |
| Two Hundred Day Average Change | 15.51155 |
| Two Hundred Day Average Change Percent | 1.2885113 |
| Type Disp | Equity |
| Volume | 180,447 |
| Website | https://www.altoneuroscience.com |
| Zip | 94,041 |